Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metreleptin and Pramlintide in Overweight and Obese Subjects
NCT00392925Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2006
- Primary completion
- Sep 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of metreleptin in obesity and Overweight (4 arms), sponsored by AstraZeneca. Primary endpoint: Mean Absolute Change From Baseline to Week 16 in Body Weight. Started Oct 2006; status: completed.
02
Drugs
metreleptin
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT00392925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00392925.